slides · global inventory
Source Note
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 110,355
Current window 74,791-74,820
Pages 3,679
Rows per page 30
Component
74,791-74,820 of 110,355
24
Trended 8 quarter view at ir.invitae.comInvitae | Results Presentation Deck | 27 slides · Invitae
Conference presentation Investor relations 1 hit
07
The slide uses a hub-and-spoke diagram to show the relationship between Kering and its various shareholder groups.Kering | Fixed Income Presentation Deck | 35 slides · Kering
Deck Investor relations Beat · Solution1 hit
11
The slide uses a pie-chart-like visual to represent strategic pillars. The revenue chart shows growth from 2012 to 2022.Kering | Fixed Income Presentation Deck | 35 slides · Kering
Deck Investor relations Beat · Solution1 hit
16
The chart is a waterfall bridge showing the transition from Q3 22 to Q3 23 revenue.Kering | Fixed Income Presentation Deck | 35 slides · Kering
Deck Investor relations Beat · FinancialsLoop · Zoom In1 hit
18
The slide uses a donut chart to show the split between Retail (78%) and Wholesale (22%) channels, with YoY growth percentages for each segment.Kering | Fixed Income Presentation Deck | 35 slides · Kering
Deck Investor relations Beat · FinancialsLoop · Zoom In1 hit
19
Kering | Fixed Income Presentation Deck | 35 slidesKering | Fixed Income Presentation Deck | 35 slides · Kering
Deck Investor relations Beat · Financials1 hit
23
The central hub-and-spoke diagram emphasizes that all four priorities are supported by a healthy financial situation and FCF generation.Kering | Fixed Income Presentation Deck | 35 slides · Kering
Deck Investor relations 1 hit
33
The 2022 dividend is split into an interim payment and a balance payment.Kering | Fixed Income Presentation Deck | 35 slides · Kering
Deck Investor relations 1 hit
05
The slide uses a grid layout to present six distinct performance indicators.Kering | Investor Presentation Deck | 63 slides · Kering
Conference presentation Investor relations Beat · Situation & Context1 hit
16
The slide uses a donut chart to show the 78/22 split between retail and wholesale, with sub-metrics for each.Kering | Investor Presentation Deck | 63 slides · Kering
Conference presentation Investor relations Beat · Evidence & Proof1 hit
27
The data highlights trends in board governance and diversity over time.Kering | Investor Presentation Deck | 63 slides · Kering
Conference presentation Investor relations Beat · Impact & Next StepsLoop · Cost Of Inaction1 hit
28
The matrix uses a 3x3 grid structure to categorize sustainability topics by impact and expectation levels.Kering | Investor Presentation Deck | 63 slides · Kering
Conference presentation Investor relations Beat · Impact & Next StepsLoop · Cost Of Inaction1 hit
29
The slide highlights alignment with SBTi, Fashion Pact, RE100, CDP, and TCFD.Kering | Investor Presentation Deck | 63 slides · Kering
Conference presentation Investor relations Beat · Impact & Next StepsLoop · Cost Of Inaction1 hit
32
Includes a visual representation of the 6x scale commitment relative to land use impact.Kering | Investor Presentation Deck | 63 slides · Kering
Conference presentation Investor relations Beat · Impact & Next StepsLoop · Cost Of Inaction1 hit
34
The diagram is a circular process model showing how different business stages contribute to circularity.Kering | Investor Presentation Deck | 63 slides · Kering
Conference presentation Investor relations Beat · Impact & Next StepsLoop · Cost Of Inaction1 hit
35
The slide uses donut charts to represent categorical breakdowns of the 47,227 total employees.Kering | Investor Presentation Deck | 63 slides · Kering
Conference presentation Investor relations Beat · Impact & Next StepsLoop · Cost Of Inaction1 hit
06
The slide uses a standard pharmaceutical pipeline table format.Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations Beat · Solution1 hit
09
Includes a mechanism of action diagram, a market data table, and a comparison of current therapy limitations.Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations 1 hit
20
Includes clinical trial identifiers and definitions of acronyms in the footer.Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations 1 hit
24
The slide uses a process flow diagram to illustrate the dose escalation (0.05 to 0.40 mg/kg) leading to MTD/RP2D expansion into four specific patient cohorts.Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations 1 hit
26
Includes a line chart showing plasma concentration over time and a table summarizing PK parameters (Cmax, AUClast, Vd, CL, t1/2).Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations 1 hit
03
The slide uses a list-based layout to present key company milestones and financial health.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · Executive Summary1 hit
04
The slide uses a two-column layout to contrast the current Phase 2 trial status with the upcoming OLE trial status.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
06
The slide uses a medical context to establish the severity of the condition and the unmet medical need.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
10
The slide displays two dot plots with error bars representing median and 25th/75th percentiles for FXN concentration changes from baseline.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
12
Data represents median and 25th/75th percentiles. Baseline values provided in footnotes.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
13
The slide establishes a baseline for FXN levels in healthy individuals to contextualize the deficiency seen in Friedreich's Ataxia (FA) patients.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
14
The slide highlights high completion rates and manageable adverse events, specifically noting injection site reactions (ISRs) as the most common side effect.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
15
FACOMS: Friedreich's Ataxia Clinical Outcome Measures StudyLarimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
17
The slide highlights the unique 'Protein replacement' approach of Nomlabofusp compared to other modalities like Mitochondrial Oxidative Stress Modifiers, Gene Expression Regulators, Pathway Modifiers, and Gene Therapy.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit